Comparative Effectiveness of Adjunctive Psychotropic Medications in Patients With Schizophrenia

JAMA Psychiatry
T Scott StroupMark Olfson

Abstract

People with schizophrenia are commonly treated with psychotropic medications in addition to antipsychotics, but there is little evidence about the comparative effectiveness of these adjunctive treatment strategies. To study the comparative real-world effectiveness of adjunctive psychotropic treatments for patients with schizophrenia. This comparative effectiveness study used US national Medicaid data from January 1, 2001, to December 31, 2010, to examine the outcomes of initiating treatment with an antidepressant, a benzodiazepine, a mood stabilizer, or another antipsychotic among adult outpatients (aged 18-64 years) diagnosed with schizophrenia who were stably treated with a single antipsychotic. Data analysis was performed from January 1, 2017, to June 30, 2018. Multinomial logistic regression models were used to estimate propensity scores to balance covariates across the 4 medication groups. Weighted Cox proportional hazards regression models were used to compare treatment outcomes during 365 days on an intention-to-treat basis. Risk of hospitalization for a mental disorder (primary), emergency department (ED) visits for a mental disorder, and all-cause mortality. The study cohort included 81 921 adult outpatients diagnosed ...Continue Reading

References

Nov 15, 1995·American Journal of Epidemiology·S L WestA Hartzema
Oct 31, 2003·American Journal of Epidemiology·Wayne A Ray
Jul 3, 2007·Psychiatric Services : a Journal of the American Psychiatric Association·Julie KreyenbuhlMark Olfson
Feb 12, 2008·Seizure : the Journal of the British Epilepsy Association·G ZaccaraM Cincotta
Dec 4, 2009·Schizophrenia Bulletin·Robert W BuchananUNKNOWN Schizophrenia Patient Outcomes Research Team (PORT)
Apr 15, 2010·JAMA : the Journal of the American Medical Association·Elisabetta PatornoSebastian Schneeweiss
Aug 3, 2010·Psychiatric Services : a Journal of the American Psychiatric Association·Elizabeth KhaykinGail L Daumit
May 9, 2012·Archives of General Psychiatry·Jari TiihonenPasi Korhonen
Jun 22, 2012·The International Journal of Neuropsychopharmacology·W Wolfgang Fleischhacker, Hiroyuki Uchida
Jan 16, 2013·Current Opinion in Psychiatry·Jacob Ballon, T Scott Stroup

❮ Previous
Next ❯

Citations

Aug 1, 2019·JAMA Psychiatry·T Scott Stroup
Jul 3, 2019·The International Journal of Neuropsychopharmacology·Sermin TotoAlexandra Neyazi
Aug 1, 2019·Acta Neuropsychiatrica·Dilhan Esen-SehirFlorian Freudenberg
Jan 16, 2020·European Journal of Clinical Pharmacology·Arto PuranenHeidi Taipale
Jan 8, 2020·Basic & Clinical Pharmacology & Toxicology·Lone Baandrup
May 14, 2020·JAMA Psychiatry·Myrna M Weissman
Dec 22, 2020·Focus : Journal of Life Long Learning in Psychiatry·Adriana Foster, Jordanne King
Feb 9, 2021·Curēus·Zain I WarriachGerardo F Ferrer
Feb 6, 2021·Journal of Psychiatric and Mental Health Nursing·Amanda Heloisa Santana da SilvaAna Carolina Guidorizzi Zanetti
Oct 1, 2021·Psychiatric Services : a Journal of the American Psychiatric Association·Natalie BareisT Scott Stroup

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here